Andere Sprachen Mangoceuticals, Inc.

Aktien

A3DY39

US56270V1061

MGRX

Realtime-Estimate Cboe BZX Andere Börsenplätze 16:33:36 17.05.2024			% 5 Tage	% 1. Jan.
0,237 ^USD	+7,68 %		-6,70 %	-12,96 %

15.05.	Mangoceuticals, Inc. meldet Ergebnis für das erste Quartal zum 31. März 2024	CI
12.04.	Mangoceuticals unterzeichnet Wertpapierkaufvertrag; mexikanische Einheit schließt technischen Vertrag mit Emifarma ab	MT

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

MangoRx Reports Revenue Growth of 108% in Q1 2024 Fueled by Amplified Customer Acquisition and Early Market Penetration	16.05.
Mangoceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	15.05.
Mangoceuticals Granted 180-Day Extension to Meet Nasdaq Minimum Bid Price Requirement and Conditional Approval of Compliance with Nasdaq’s Minimum Stockholders’ Equity Requirement	02.05.
Mangoceuticals Acquires Global Patent Portfolio to Revolutionize Preventive Care	25.04.
Mangoceuticals Signs Securities Purchase Deal; Mexican Unit Enters Technical Deal With Emifarma	12.04.
Mangoceuticals Subsidiary, MangoRx Mexico, Executes Technical Agreement with Mexican Pharmaceutical Manufacturer for Initial Development and Production of its Mango Erectile Dysfunction (ED) Products	12.04.
Mangoceuticals, Inc. announced that it expects to receive CAD 1.5 million in funding from Platinum Point Capital LLC	04.04.
Certain Warrants of Mangoceuticals, Inc. are subject to a Lock-Up Agreement Ending on 21-MAR-2024.	21.03.
Certain Options of Mangoceuticals, Inc. are subject to a Lock-Up Agreement Ending on 21-MAR-2024.	21.03.
Certain Common Stock of Mangoceuticals, Inc. are subject to a Lock-Up Agreement Ending on 21-MAR-2024.	21.03.
Top Premarket Gainers	20.03.
Certain Common Stock of Mangoceuticals, Inc. are subject to a Lock-Up Agreement Ending on 18-MAR-2024.	18.03.
Certain Warrants of Mangoceuticals, Inc. are subject to a Lock-Up Agreement Ending on 18-MAR-2024.	18.03.
Certain Options of Mangoceuticals, Inc. are subject to a Lock-Up Agreement Ending on 18-MAR-2024.	18.03.
MangoRx Officially Launches ‘PRIME’ by MangoRx, Powered by Kyzatrex®️ FDA Approved Oral Testosterone Replacement Therapy (TRT) Treatment	12.03.
Mangoceuticals, Inc. Officially Launches ?PRIME? by MangoRx, Powered by Kyzatrex® FDA Approved Oral Testosterone Replacement Therapy Treatment	12.03.
MangoRx Launches Direct-To-Clinics Sales Division to Drive and Fuel Customer Acquisition and Revenue Growth	20.02.
Mangoceuticals, Inc. Launches Direct-To-Clinics Sales Division to Drive and Fuel Customer Acquisition and Revenue Growth	20.02.
MANGORX AWARDS SAN FRANCISCO TEAM FREE MANGORX ED PRODUCTS FOR ONE YEAR FOLLOWING BIG GAME LOSS TO KANSAS CITY	13.02.
MANGORX TO OFFER THE BIG GAME’S LOSING TEAM A FREE ONE YEAR SUPPLY OF ITS ED PRODUCT, MANGO, TO HELP RAISE… SPIRITS	06.02.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Mangoceuticals, Inc.

Aktien

A3DY39

US56270V1061

MGRX

Andere Sprachen

Filter